News | ASNC | August 12, 2022

Flurpiridaz Clinical Trial Results Will be Announced at ASNC2022

Jamshid Maddahi, MD, FASNC

August 12, 2022 — The results of “A Phase 3, Open-label, Multicenter Study of Flurpiridaz (F18) Injection for Positron Emission Tomography (PET) Imaging Assessment of Myocardial Perfusion in Patients Referred for Invasive Angiography Because of Suspected Coronary Artery Disease (CAD)” will be presented for the first time at ASNC’s 27th Annual Scientific Session and Exhibition, which will convene September 8-11, 2022, in Orlando, Florida. 

“Cardiac imagers around the world have been eager for the results of this important trial, which could set the stage for the approval of the first new nuclear cardiology perfusion radiopharmaceutical since the mid-1990s as well as the expanded use of cardiac PET imaging,” says ASNC President Dennis A. Calnon, MD, MASNC. “We are delighted to host the premier presentation of these new data when the nuclear cardiology community reunites at ASNC2022." 

The phase 3 flurpiridaz trial was designed to answer two questions: 

What is the diagnostic efficacy of flurpiridaz injection PET myocardial perfusion imaging (MPI) for detecting significant CAD? 

How does the diagnostic efficacy of flurpiridaz injection PET MPI compare with SPECT MPI in detecting CAD? 

On Friday, September 9, during the ASNC2022 Opening Plenary Session, Jamshid Maddahi, MD, FASNC, the study’s principal investigator and director of the Clinical PET Scanning Center at UCLA Health, will present the trial’s findings. 

ASNC2022 also will feature a special session titled “F18 Flurpiridaz: Transforming Patient Care with Cardiac PET.” This case-based session will feature an interactive discussion of “The Flurpiridaz Journey” and the practical implications of the trial results for cardiac imaging labs and clinicians’ test selection. Scheduled for Saturday, September 10, at 1:00 PM (U.S. EDT), the session will be moderated by Rob S.B. Beanlands, MD, MASNC, with faculty including Timothy M. Bateman, MD, MASNC, Daniel S. Berman, MD, MASNC, Panithaya Chareonthaitawee, MD, Gary V. Heller, MD, PhD, MASNC, and Jamshid Maddahi, MD, FASNC. 

Flurpiridaz has several properties that make it intriguing for cardiac imagers: 

  • Ability to incorporate exercise testing with cardiac PET imaging 
  • Unit-dose delivery from a regional cyclotron 
  • High first-pass extraction fraction with the high spatial resolution associated with F18 radiopharmaceuticals 

“This trial has the potential to transform patient care, which fits perfectly with the ASNC2022 theme, ‘Bold Approaches for Transforming Patient Care,’” says ASNC2022 Program Chair Karthikeyan Ananthasubramaniam, MD, FASNC. “If you are a cardiac imaging professional, be sure to attend ASNC2022 to hear the new data for yourself and to hear from experts on what the results will mean for your lab and your patients.” 

For more information: https://www.asnc.org/register 

Related PET Imaging Content: 

VIDEO: Practical Considerations for Starting a Cardiac PET-CT Program — Interview with Rupa Sanghani, M.D. 

6 Trends in Cardiac Nuclear Imaging at the ASNC 2019 Meeting 

VIDEO: PET vs. SPECT in Nuclear Cardiology and Recent Advances in Technology — Interview with Prem Soman, M.D. 

Recent Advances in Cardiac Nuclear Imaging Technology 

VIDEO: Trends in Nuclear Cardiology Imaging — Interview with David Wolinsky, M.D. 

Image Gallery From the American Society of Nuclear Cardiology 2019 Meeting 

 


Related Content

News | Cardiac Imaging

September 2, 2022 — A randomized trial in more than 45,000 men has suggested that cardiovascular screening including ...

Home September 02, 2022
Home
News | Cardiac Imaging

September 2, 2022 — In an innovative, pragmatic randomized trial, high-dose influenza vaccination in older adults was ...

Home September 02, 2022
Home
News | Cardiac Imaging

August 25, 2022 — Imperfect current propagation in the heart is at the root of most cardiac diseases. Thanks to a novel ...

Home August 25, 2022
Home
News | Cardiac Imaging

July 14, 2022 – AvoMD, a next-generation application-based clinical decision support platform, is working with the ...

Home July 14, 2022
Home
Feature | Cardiac Imaging | By Ronny Shalev, Ph.D.

Artificial intelligence’s (AI) applicability in cardiac imaging is rapidly growing and was a major topic of discussion ...

Home June 28, 2022
Home
News | Cardiac Imaging

June 24, 2022 — The Radiological Society of North America (RSNA) reports that Coronary Artery Calcium (CAC) scoring with ...

Home June 24, 2022
Home
News | Cardiac Imaging

June 23, 2022 — New research from the Smidt Heart Institute at Cedars-Sinai shows for the first time that the path ...

Home June 23, 2022
Home
News | Cardiac Imaging

May 2, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), routine visual ordinal coronary artery calcium ...

Home May 02, 2022
Home
News | Cardiac Imaging

April 11, 2022 — Radiation to the heart during treatment for locally advanced lung cancer is associated with an ...

Home April 11, 2022
Home
News | Cardiac Imaging
February 21, 2022 – Acute coronary syndromes (such as heart attacks) and strokes are a leading cause of morbidity and ...
Home February 21, 2022
Home
Subscribe Now